The 9th International Conference on Alzheimer's and Parkinson's Diseases: Advances, Concepts and New Challenges

This congress covers over 40 Alzheimer's and Parkinson's Diseases (AD/PD) and neurodegenerative related topics and features presentations and discussions from over 100 acclaimed scientists and clinicians from 28 countries on the latest methodologies, research and breakthroughs in AD/PD.

Deadline for submission of abstracts: October 15, 2008

 

From: Wed, 11/03/2009 - 09:00
To: Sun, 15/03/2009 - 19:00
Prague, Czech Republic
Conference organiser - Kenes International
adpd@kenes.com
http://www2.kenes.com/adpd/Pages/Home.aspx

 Around 2,500 participants are expected to attend. The groundbreaking series of AD/PD conferences provides a unique platform for presentations on, and discussion of the most up-to-date techniques and research in both AD/PD, as well as the integration between them and related neurodegenerative illnesses.

Preliminary list of topics:

A. Etiology, pathogenesis, risk factors, clinical features, points of convergence and differences in:
Alzheimer's Disease (AD) including non-cognitive aspects
Parkinson's Disease (PD), PD dementia, atypical PD & non motor symptoms in PD
Minimal cognitive impairment (MCI) and Age-Associated Memory Impairment (AAMI)
Vascular dementia (VAD)
Cerebral amyloid angiopathy (CAA)
Dementia with Lewy Bodies (DLB)
Frontotemporal dementia (FTD)
Movement disorders other than PD (Tics, Restless Legs Syndrome, Dystonia)
Depression and psychotic states in AD/PD
Neurodevelopment and neurodegeneration
Head injury
Cognitive impairments in autoimmune disorders
Amyotrophic lateral sclerosis (ALS) and Huntington's Disease (HD)
Multiple systems atrophy
Progranulinopathies and other Protein Misfolding Diseases (PMD)

--------------------------------------------------------------------------------
B. Genetics of neurodegenerative diseases
--------------------------------------------------------------------------------
C. Pharmacogenomics in prevention and treatment
--------------------------------------------------------------------------------
D. Epidemiology, pharmacoeconomics and quality of life
--------------------------------------------------------------------------------
E. Neuroimaging
--------------------------------------------------------------------------------
F. Biomarkers and diagnostics in prevention and treatment
--------------------------------------------------------------------------------
G. CNS-periphery communication in neurodegenerative diseases
--------------------------------------------------------------------------------
H. Biology of APP, Abeta, Abeta oligomers and beta- amyloid
--------------------------------------------------------------------------------
I. Tau, cytoskeleton and tauopathies
--------------------------------------------------------------------------------
J. Energy metabolism and oxidative stress
--------------------------------------------------------------------------------
K. Apolipoprotein-E
--------------------------------------------------------------------------------
L. Inflammation
--------------------------------------------------------------------------------
M. Synucleopathies
--------------------------------------------------------------------------------
N. Animal models of neurodegenerative diseases
--------------------------------------------------------------------------------
O. Treatment and Disease Modification Strategies:
Modulation of secretases
Aggregation inhibitors
Modulation of kinases and phosphatases
Neurotransmitter-based treatments
Cholesterol and lipids
Low molecular weight glycosaminoglycans (GAGs) and GAG-mimetics
Neurotrophic factors and inhibitors
Immunotherapies and antibodies
Stem cells
Gene therapies
New drug delivery systems/ methods
Neurotransplantation and neurosurgery
Novel pharmacological compounds
Novel biological agents

--------------------------------------------------------------------------------
P. Drug discovery and development
--------------------------------------------------------------------------------
Q. Late breaking results
--------------------------------------------------------------------------------